tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Dec 26;92:107329.
doi: 10.1016/j.intimp.2020.107329. Online ahead of print.
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
Parvaneh Baghaei[SUP] 1 [/SUP], Farzaneh Dastan[SUP] 2 [/SUP], Majid Marjani[SUP] 1 [/SUP], Afshin Moniri[SUP] 1 [/SUP], Zahra Abtahian[SUP] 1 [/SUP], Somayeh Ghadimi[SUP] 3 [/SUP], Melika Valizadeh[SUP] 3 [/SUP], Jalal Heshmatnia[SUP] 1 [/SUP], Maryam Sadat Mirenayat[SUP] 4 [/SUP], Atefeh Abedini[SUP] 4 [/SUP], Arda Kiani[SUP] 5 [/SUP], Alireza Eslaminejad[SUP] 5 [/SUP], Seyed MohammadReza Hashemian[SUP] 1 [/SUP], Hamidreza Jamaati[SUP] 4 [/SUP], Alireza Zali[SUP] 6 [/SUP], Ali Akbar Velayati[SUP] 1 [/SUP], Payam Tabarsi[SUP] 7 [/SUP]
Affiliations
Abstract
Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-β1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-β1-a and Lopinavir 400 mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-β1-a on outcome and all-cause mortality. 152 cases in IFN-β1-a group and 304 cases as control group were included. IFN-β1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p = 0.001) and (34% vs. 24%, p = 0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-β1-a (HR 5.12, 95% CI: 2.77-9.45), comorbidity (HR 2.28, 95% CI: 1.13-4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56-4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-β1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-β1-a in COVID-19 treatment.
Keywords: Covid-19; IFN-β1-a; Intensive care; Mortality; Outcome; Survival.
. 2020 Dec 26;92:107329.
doi: 10.1016/j.intimp.2020.107329. Online ahead of print.
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
Parvaneh Baghaei[SUP] 1 [/SUP], Farzaneh Dastan[SUP] 2 [/SUP], Majid Marjani[SUP] 1 [/SUP], Afshin Moniri[SUP] 1 [/SUP], Zahra Abtahian[SUP] 1 [/SUP], Somayeh Ghadimi[SUP] 3 [/SUP], Melika Valizadeh[SUP] 3 [/SUP], Jalal Heshmatnia[SUP] 1 [/SUP], Maryam Sadat Mirenayat[SUP] 4 [/SUP], Atefeh Abedini[SUP] 4 [/SUP], Arda Kiani[SUP] 5 [/SUP], Alireza Eslaminejad[SUP] 5 [/SUP], Seyed MohammadReza Hashemian[SUP] 1 [/SUP], Hamidreza Jamaati[SUP] 4 [/SUP], Alireza Zali[SUP] 6 [/SUP], Ali Akbar Velayati[SUP] 1 [/SUP], Payam Tabarsi[SUP] 7 [/SUP]
Affiliations
- PMID: 33412395
- PMCID: PMC7762801
- DOI: 10.1016/j.intimp.2020.107329
Abstract
Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-β1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-β1-a and Lopinavir 400 mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-β1-a on outcome and all-cause mortality. 152 cases in IFN-β1-a group and 304 cases as control group were included. IFN-β1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p = 0.001) and (34% vs. 24%, p = 0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-β1-a (HR 5.12, 95% CI: 2.77-9.45), comorbidity (HR 2.28, 95% CI: 1.13-4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56-4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-β1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-β1-a in COVID-19 treatment.
Keywords: Covid-19; IFN-β1-a; Intensive care; Mortality; Outcome; Survival.